Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan® IM, Adequan® IA, and Adequan® Canine provide the following supply interruption update:
Protecting horse health
Luitpold has been working closely with the FDA to assure that Adequan® is made available as soon as possible and now anticipate release of Adequan® products to the market beginning in late August, 2013.
In 2012, Luitpold renovated and upgraded its Shirley, New York manufacturing facility as part of its commitment to improving the quality of its operations. These renovations affected Luitpold’s ability to manufacture and release Adequan®, resulting in the current shortages that exist in the marketplace.
Luitpold has been working closely with the Food and Drug Administration to assure that Adequan® is made available as soon as possible. As a result of these efforts, we have been able to revise our target date for product availability from our original estimate of the first quarter 2014. We now anticipate release of Adequan® products to the market beginning in late August, 2013.
Luitpold remains committed to resuming its manufacture and release of Adequan® products. We understand how critically important the Adequan® brands are to the health and well-being of the animals receiving treatment.
The company has established a dedicated webpage Adequan where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.
Adequan® IM and IA are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan® Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.